Q2 Earnings Forecast for LENZ Issued By HC Wainwright

LENZ Therapeutics, Inc. (NASDAQ:LENZ) – Stock analysts at HC Wainwright issued their Q2 2025 earnings estimates for LENZ Therapeutics in a research report issued on Thursday, March 20th. HC Wainwright analyst M. Caufield forecasts that the company will post earnings per share of ($0.60) for the quarter. The consensus estimate for LENZ Therapeutics’ current full-year earnings is ($2.18) per share. HC Wainwright also issued estimates for LENZ Therapeutics’ Q4 2025 earnings at ($0.66) EPS, FY2025 earnings at ($2.52) EPS, FY2026 earnings at ($2.18) EPS, FY2027 earnings at ($1.02) EPS, FY2028 earnings at $0.18 EPS and FY2029 earnings at $1.45 EPS.

LENZ Therapeutics (NASDAQ:LENZ) last issued its earnings results on Wednesday, March 19th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.04).

A number of other equities research analysts have also recently commented on the company. Citigroup raised their price target on LENZ Therapeutics from $44.00 to $47.00 and gave the company a “buy” rating in a report on Thursday, March 20th. TD Cowen began coverage on shares of LENZ Therapeutics in a report on Tuesday, March 18th. They issued a “buy” rating and a $60.00 price target for the company. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, LENZ Therapeutics presently has a consensus rating of “Buy” and an average price target of $41.67.

LENZ Therapeutics Stock Performance

Shares of LENZ Therapeutics stock opened at $26.43 on Monday. LENZ Therapeutics has a one year low of $14.42 and a one year high of $38.93. The stock has a market cap of $726.85 million, a P/E ratio of -5.54 and a beta of 0.58. The stock’s fifty day moving average is $24.30 and its 200 day moving average is $27.12.

Institutional Investors Weigh In On LENZ Therapeutics

Large investors have recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in shares of LENZ Therapeutics by 5.3% in the fourth quarter. Vanguard Group Inc. now owns 1,178,447 shares of the company’s stock worth $34,022,000 after acquiring an additional 59,630 shares during the period. Price T Rowe Associates Inc. MD increased its stake in shares of LENZ Therapeutics by 83.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 822,957 shares of the company’s stock valued at $23,760,000 after purchasing an additional 374,326 shares in the last quarter. Paradigm Biocapital Advisors LP purchased a new stake in LENZ Therapeutics in the 4th quarter worth $22,243,000. State Street Corp lifted its holdings in LENZ Therapeutics by 18.7% in the 3rd quarter. State Street Corp now owns 289,154 shares of the company’s stock valued at $6,865,000 after purchasing an additional 45,600 shares in the last quarter. Finally, Alyeska Investment Group L.P. boosted its position in LENZ Therapeutics by 16.4% during the fourth quarter. Alyeska Investment Group L.P. now owns 142,113 shares of the company’s stock worth $4,103,000 after acquiring an additional 20,000 shares during the last quarter. Hedge funds and other institutional investors own 54.32% of the company’s stock.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.